Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Treasury Shares (2016 - 2025)

Corcept Therapeutics' Treasury Shares history spans 8 years, with the latest figure at $966.6 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 38.84% year-over-year to $966.6 million; the TTM value through Dec 2025 reached $966.6 million, up 38.84%, while the annual FY2025 figure was $966.6 million, 38.84% up from the prior year.
  • Treasury Shares for Q4 2025 was $36.6 million at Corcept Therapeutics, up from $600000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $36.6 million in Q4 2025 and bottomed at $20000.0 in Q1 2024.
  • The 5-year median for Treasury Shares is $991000.0 (2021), against an average of $6.8 million.
  • The largest annual shift saw Treasury Shares skyrocketed 441.48% in 2021 before it increased 5.97% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $410.4 million in 2021, then grew by 11.14% to $456.1 million in 2022, then soared by 39.23% to $635.1 million in 2023, then grew by 9.62% to $696.2 million in 2024, then surged by 38.84% to $966.6 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Treasury Shares are $966.6 million (Q4 2025), $923.3 million (Q3 2025), and $866.9 million (Q2 2025).